JP2024506067A5 - - Google Patents

Info

Publication number
JP2024506067A5
JP2024506067A5 JP2023548215A JP2023548215A JP2024506067A5 JP 2024506067 A5 JP2024506067 A5 JP 2024506067A5 JP 2023548215 A JP2023548215 A JP 2023548215A JP 2023548215 A JP2023548215 A JP 2023548215A JP 2024506067 A5 JP2024506067 A5 JP 2024506067A5
Authority
JP
Japan
Prior art keywords
cells
stem
group
modified
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/050075 external-priority patent/WO2022170384A1/en
Publication of JP2024506067A publication Critical patent/JP2024506067A/ja
Publication of JP2024506067A5 publication Critical patent/JP2024506067A5/ja
Pending legal-status Critical Current

Links

JP2023548215A 2021-02-10 2022-02-09 増強された機能を有する幹細胞由来免疫細胞を生成するための方法および組成物 Pending JP2024506067A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163147933P 2021-02-10 2021-02-10
US63/147,933 2021-02-10
US202163236828P 2021-08-25 2021-08-25
US63/236,828 2021-08-25
PCT/AU2022/050075 WO2022170384A1 (en) 2021-02-10 2022-02-09 Methods and compositions for generating stem cell-derived immune cells with enhanced function

Publications (2)

Publication Number Publication Date
JP2024506067A JP2024506067A (ja) 2024-02-08
JP2024506067A5 true JP2024506067A5 (cg-RX-API-DMAC10.html) 2025-02-18

Family

ID=82838866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548215A Pending JP2024506067A (ja) 2021-02-10 2022-02-09 増強された機能を有する幹細胞由来免疫細胞を生成するための方法および組成物

Country Status (7)

Country Link
US (1) US20240117311A1 (cg-RX-API-DMAC10.html)
EP (1) EP4291660A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024506067A (cg-RX-API-DMAC10.html)
KR (1) KR20240004245A (cg-RX-API-DMAC10.html)
AU (1) AU2022220754A1 (cg-RX-API-DMAC10.html)
CA (1) CA3211013A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022170384A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119432926B (zh) * 2024-11-18 2025-08-26 首都医科大学附属北京儿童医院 一种系统性红斑狼疮小鼠模型的构建方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039513A2 (en) * 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
ES2918501T3 (es) * 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US12012598B2 (en) * 2016-08-12 2024-06-18 Toolgen Incorporated Manipulated immunoregulatory element and immunity altered thereby
US12275963B2 (en) * 2017-05-08 2025-04-15 Toolgen Incorporated Artificially manipulated immune cell
CN114127268A (zh) * 2019-05-02 2022-03-01 塞利亚德股份公司 具有多重化的抑制性rna的细胞
CN115885038A (zh) * 2020-06-17 2023-03-31 国立大学法人京都大学 表达嵌合抗原受体的免疫活性细胞

Similar Documents

Publication Publication Date Title
US20230287348A1 (en) Method for the generation of genetically modified cells
Dickinson et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia
Yanir et al. Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions
Lv et al. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
KR102954207B1 (ko) 면역요법을 위한 t 세포 내 tgfbr2의 crispr-cas9 편집 방법, 조성물 및 성분
Yu et al. Dendritic cell regulation of graft-vs.-host disease: immunostimulation and tolerance
Peng et al. Natural killer cell memory: progress and implications
Litjens et al. Potential beneficial effects of cytomegalovirus infection after transplantation
Leung Use of NK cell activity in cure by transplant
JP2024054194A5 (cg-RX-API-DMAC10.html)
Berglund et al. Advances in umbilical cord blood cell therapy: the present and the future
Flahou et al. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity
US6586192B1 (en) Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
Maier et al. Efficient clinical scale gene modification via zinc finger nuclease–targeted disruption of the HIV co-receptor CCR5
Della Chiesa et al. Impact of HCMV infection on NK cell development and function after HSCT
JP2022520402A5 (cg-RX-API-DMAC10.html)
JP2020505934A5 (cg-RX-API-DMAC10.html)
Broxmeyer et al. Cord blood hematopoietic cell transplantation
Drummond et al. Concise review: telomere biology in normal and leukemic hematopoietic stem cells
Babor et al. The role of KIR genes and ligands in leukemia surveillance
Mrahleh et al. Human Wharton’s jelly-derived mesenchymal stromal cells primed by tumor necrosis factor-α and interferon-γ modulate the innate and adaptive immune cells of type 1 diabetic patients
Fang et al. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Zhang et al. Adoptive T cell therapy following haploidentical hematopoietic stem cell transplantation
Zhang et al. Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals
Moretta et al. In vitro evaluation of graft-versus-graft alloreactivity as a tool to identify the predominant cord blood unit before double cord blood transplantation